News Neurocrine achieves a first with tardive dyskinesia drug Ing... The FDA has approved Neurocrine Bioscience’s Ingrezza, the first ever licensed treatment for tardive dyskinesia or TD.
News Brent Saunders ejects from Bausch + Lomb once again Brent Saunders' second stint as chief executive of eye care company Bausch + Lomb has come to an end.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
